CN115671169B - A composition with sleep improving effect - Google Patents
A composition with sleep improving effect Download PDFInfo
- Publication number
- CN115671169B CN115671169B CN202211413126.2A CN202211413126A CN115671169B CN 115671169 B CN115671169 B CN 115671169B CN 202211413126 A CN202211413126 A CN 202211413126A CN 115671169 B CN115671169 B CN 115671169B
- Authority
- CN
- China
- Prior art keywords
- oil
- composition
- peony seed
- acer truncatum
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 230000000694 effects Effects 0.000 title claims abstract description 24
- 235000019198 oils Nutrition 0.000 claims abstract description 52
- 241000736199 Paeonia Species 0.000 claims abstract description 45
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 45
- 241000219226 Acer truncatum Species 0.000 claims abstract description 41
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 41
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 14
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 10
- 239000011709 vitamin E Substances 0.000 claims abstract description 10
- 229940046009 vitamin E Drugs 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 7
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 7
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 claims abstract description 6
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 claims abstract description 6
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 6
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 235000020778 linoleic acid Nutrition 0.000 claims description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 1
- 230000037007 arousal Effects 0.000 abstract description 14
- 230000014509 gene expression Effects 0.000 abstract description 11
- 101150041053 GABRA1 gene Proteins 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 8
- 101100024151 Danio rerio mtnr1aa gene Proteins 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 abstract description 2
- 239000003921 oil Substances 0.000 description 45
- 241000252212 Danio rerio Species 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 14
- 230000006872 improvement Effects 0.000 description 13
- 239000000341 volatile oil Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 238000007127 saponification reaction Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 5
- 229960003987 melatonin Drugs 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229960004232 linoleic acid Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 206010062519 Poor quality sleep Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010017472 Fumbling Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001102 lavandula vera Substances 0.000 description 2
- 235000018219 lavender Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241001529821 Agastache Species 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 101150105788 mtnr1aa gene Proteins 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- YLLIGHVCTUPGEH-UHFFFAOYSA-M potassium;ethanol;hydroxide Chemical compound [OH-].[K+].CCO YLLIGHVCTUPGEH-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a composition with a sleep improving effect, which is prepared from the following raw materials in parts by weight: 1 to 5 parts of peony seed oil, 1 to 5 parts of acer truncatum oil and 0.5 to 2.5 parts of vitamin E. According to the invention, peony seed oil containing high-purity alpha-linolenic acid and linoleic acid, high-purity arachidonic acid and nervonic acid and acer truncatum oil are mixed in a specific proportion, and an animal test proves that the obtained compound has the effect of improving sleep, and is specifically characterized in that the arousal activity and the arousal total time are reduced, and the relative expression of mtnr1aa and gabra1 genes is up-regulated. Compared with the independent peony seed oil, the acer truncatum oil and the VE, the composition provided by the invention has better efficacy in improving sleep, and has practical popularization and application values.
Description
Technical Field
The invention relates to a composition with sleep improving effect.
Background
Sleep is an essential element of survival, and insufficient sleep can lead to various dysfunctions. According to world health organization statistics, 27% of people worldwide are suffering from insomnia, and this value is continuously rising. Currently, sleep problems have become one of the general concerns in the medical community. Although the chemical medicine for treating insomnia is rapidly developed in the past few years, the curative effect of the chemical medicine is poor due to toxic and side effects and possibly generated dependence, such as melatonin, and long-term administration of the chemical medicine not only can lead to poor effect of treating insomnia, but also can lead to aggravation of sleep rhythm disorder and long-term neurasthenia. Therefore, it is important to develop a pure natural medicine with no toxic or side effect and sleep quality improvement.
The plant essential oil is a general term for volatile oily liquid substances with aroma and/or fragrance, which are extracted from flowers, roots, stems, leaves, branches, trunks, barks, fruits or secretions of aromatic plants by distillation, carbonization, extraction, squeezing, adsorption or absorption and other processes. The natural plant essential oil contains 696 kinds, such as herba Menthae essential oil, fructus Litseae essential oil, lavender essential oil, herba Agastaches essential oil, etc. The plant essential oil has small molecular weight and certain biological activity, and can also be used for contributing to the alleviation of sleep disorder. Researches prove that the lavender essential oil, the lemon essential oil, the jasmine essential oil, the peony seed oil, the acer truncatum oil and the like have good sedative effects, have certain regulating capability on a nervous system, can relieve stress and anxiety symptoms of a body, enable the body to keep a loose state and improve sleep, and have poor effects.
At present, no report of using the combination of peony seed oil, acer truncatum oil and vitamins for improving sleep quality exists.
Disclosure of Invention
In order to solve the problems, the invention provides a composition with the function of improving sleep, which is prepared from the following raw materials in parts by weight:
1 to 5 parts of peony seed oil, 1 to 5 parts of acer truncatum oil and 0.5 to 2.5 parts of vitamin E.
Further, the material is prepared from the following raw materials in parts by weight:
1 part of peony seed oil, 1 part of acer truncatum oil and 0.5 part of vitamin E.
Further, the relative content of linoleic acid in the peony seed oil is more than 17%, and the relative content of alpha-linolenic acid is more than 58%.
Further, the relative content of linoleic acid in the acer truncatum oil is more than 30%, the relative content of arachidonic acid is more than 12%, and the relative content of nervonic acid is more than 4%.
Further, the preparation is prepared by taking peony seed oil, acer truncatum oil and vitamin E as active ingredients and adding pharmaceutically acceptable auxiliary materials.
Further, the preparation is an external preparation.
Further, the external preparation is a solution, an emulsion, a gel, an aerosol, a film coating agent or a emplastrum.
The invention also provides a preparation method of the composition, which comprises the following steps:
1) Weighing the raw materials according to the proportion;
2) Mixing the above materials, and adding pharmaceutically acceptable adjuvants.
The invention finally provides application of the composition in preparing a medicament for improving sleep.
The composition for improving sleep is prepared by mixing peony seed oil containing high-purity alpha-linolenic acid and linoleic acid, high-purity arachidonic acid and nervonic acid and acer truncatum oil with vitamin E according to a specific proportion, and proved by animal experiments to have obvious sleep improving effect, and is particularly characterized in that the arousal activity and the arousal total time are reduced, and the relative expression of mtnr1aa and gabra1 genes is up-regulated. Compared with the independent peony seed oil, the acer truncatum oil and the VE, the composition provided by the invention has better efficacy in improving sleep, and has practical popularization and application values.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Drawings
FIG. 1 is a typical view of the motion trail of zebra fish after sample processing
FIG. 2 sample treatment followed by zebra fish wake activity
FIG. 3 total time of wakefulness of zebra fish after sample treatment
FIG. 4 relative expression level of mtnr1aa gene
FIG. 5 relative expression level of gabra1 gene
Detailed Description
The raw materials and equipment used in the specific embodiment of the invention are all known products, and are obtained by purchasing commercial products, wherein the peony seed oil and the acer truncatum oil are crude products of the peony seed oil and the acer truncatum oil obtained by physical squeezing or supercritical fluid extraction or subcritical fluid extraction of the peony seed and acer truncatum seeds, and then the peony seed oil and the acer truncatum oil with high purity alpha-linolenic acid and linoleic acid and the acer truncatum oil with high content of arachidonic acid and nervonic acid are respectively obtained by one or more combined purification and separation methods of column chromatography, low-temperature crystallization, molecular distillation and the like. The preparation method comprises the following steps:
preparation of peony seed oil:
(1) Drying fresh, clean, mildew-free and pest-free peony seeds at 50-60 ℃, crushing, sieving (40-100 mesh sieve), rolling (20-40 min), and drying (50-60 ℃) for 4-5h, wherein the obtained peony seed powder and an extracting agent n-butane are mixed according to a ratio of 1:5, carrying out subcritical fluid extraction on the mixture according to the volume ratio (g/mL) of solute to obtain a peony seed coat extract;
(2) Separating the extract by vacuum heating method (separation pressure 0.5-1.5Mpa and separation temperature 60-70deg.C) to obtain oily extract, standing at room temperature for 50-60min to obtain peony seed oil;
(3) Performing primary purification on peony seed oil after saponification reaction to obtain a saponification reactant (wherein the saponification reaction temperature is 35-55 ℃ and the saponification reaction time is 45-120 min);
(4) Ethanol in the saponification reactant is removed by reduced pressure distillation, and the saponification reactant after the ethanol removal is immediately subjected to the volume ratio of 1: 2-5, adding sulfuric acid aqueous solution (4% -8% of mass percentage concentration), mixing and stirring, separating oil phase, washing with water to neutrality, and drying with anhydrous sodium sulfate to obtain mixed fatty acid;
(5) The mixed fatty acid solution is subjected to melt crystallization to obtain high-purity alpha-linolenic acid, wherein the temperature, the cooling time and the maintaining time of an inner layer and an outer layer in a melting layer crystallizer with a double-layer jacket are required to be controlled, and the crystallization of the melting layer is facilitated: controlling the temperature of the outer jacket to be reduced to-10 to-35 ℃ within 100-150min, controlling the temperature of the inner jacket to be reduced to-12 to-35 ℃ within 100-150min, and maintaining for 3-6h; collecting mother liquor of melt layer crystallization to obtain peony seed oil containing high-purity alpha-linolenic acid and linoleic acid.
Preparation of Acer truncatum Bunge oil:
(1) Drying fresh, clean, mildew-free and insect-free Acer truncatum seed kernel at 50-60deg.C, pulverizing, sieving (40-100 mesh sieve), rolling (30-40 min), and oven drying (55-60deg.C) for 3-4 hr to obtain Acer truncatum seed kernel powder and extracting agent n-butane according to a ratio of 1:6, carrying out subcritical fluid extraction on the material solute amount volume ratio (g/mL) to obtain Acer truncatum seed kernel extract;
(2) Separating the extract by vacuum heating method (separation pressure 0.5-1.5Mpa and separation temperature 60-75deg.C) to obtain oily extract, standing at room temperature for 55-60min to obtain Acer Truncatum Bunge oil;
(3) Acer truncatum oil is prepared according to the following formula 1:2 (g/mL) is added with 2M potassium hydroxide ethanol solution in proportion, after uniform mixing, water bath reaction is carried out for 90min at 80 ℃, then pure water with the volume of 1 time and normal hexane with the volume of 1 time are sequentially added into the product, and after light shaking, standing and layering are carried out, an upper organic phase is removed, and a lower layer is obtained after separation; the pH of the lower layer solution is adjusted to 1-2 by adding 3M hydrochloric acid solution, and the lower layer solution is extracted for 2 times by adding n-hexane with the volume of 2 times. Mixing the organic phases, washing with a small amount of pure water to neutrality, drying and filtering with anhydrous sodium sulfate, and removing n-hexane by rotary evaporation at 45 ℃ to obtain mixed fatty acid;
(4) The mass volume ratio of the mixed fatty acid solution to the ethanol is 1:3 (g/mL) and crystallizing at low temperature of-40 ℃ for 4-5h, filtering to obtain crystals, and mixing with filtrate obtained by removing ethanol solvent by rotary evaporation to obtain the Acer Truncatum Bunge oil with high content of arachidonic acid and nervonic acid.
The GC-MS analysis results of the fatty acids of the peony seed oil and the acer truncatum oil prepared by the process are as follows:
note that: the relative fatty acid content is the ratio of the peak area of the fatty acid to the sum of the peak areas of all components in the GC-MS spectrum.
EXAMPLE 1 inventive composition
Mixing peony seed oil 1 part, acer truncatum oil 1 part and vitamin E0.5 part.
EXAMPLE 2 compositions of the invention
Mixing peony seed oil 2 parts, acer truncatum oil 2 parts and vitamin E2 parts.
EXAMPLE 3 compositions of the invention
Mixing peony seed oil 5 parts, acer truncatum oil 5 parts and vitamin E1.5 parts.
The beneficial effects of the present invention are further illustrated by the following test examples
Test example 1 evaluation of sleep improvement efficacy
The invention is an evaluation of sleep improvement efficacy
Early animal preliminary experiments found that the volume ratio was 2:2: the compound of the peony seed oil, the acer truncatum oil and the vitamin E is obviously higher than the compound (P < 0.05) with other dosage proportions in terms of the arousal activity and the arousal total time reduction degree, so that the sleep improvement effect evaluation is carried out by using the composition of 1 part of the peony seed oil, 1 part of the acer truncatum oil and 0.5 part of the vitamin E.
1. Detection material
1.1. Sample formulation information
Peoney Oil (prepared as in example 1) was heated and then prepared as a 100 μl/mL stock solution with 10% dmso.
Positive control: melatonin, white powder, lot number F1804064, shanghai Ala Biochemical technology Co., ltd.) was stored in the shade. Stock solution of 12.5mg/mL was prepared with DMSO and stored at-20 ℃.
1.2. Experimental animal
Zebra fish are all cultivated in water for fish cultivation at 28 deg.C (water quality: 200mg instant sea salt is added into 1L reverse osmosis water, conductivity is 450-550 mu S/cm, pH is 6.5-8.5, hardness is 50-100 mg/LCaCO) 3 ) The experimental animal use license number is provided by the breeding of the fish culture center of the company: SYXK (Zhe) 2022-0004, the feeding management meets the requirements of International AAALAC authentication (authentication number: 001458).
Wild type AB strain zebra fish is bred in a natural pairing mating breeding mode. Zebra fish aged 5 days post fertilization (5 dpf) were used for maximum detection concentration (MTC) determination of sleep improvement efficacy and efficacy evaluation thereof.
1.3. Instrument, consumable and reagent
Dissecting microscope (SZX 7, OLYMPUS, japan); CCD camera (VertA 1, shanghai Tusen Vision technologies Co., ltd.); precision electronic balances (CP 214, OHAUS, USA); zebra fish behavioral analysis system (Zebra Lab 3.22.3.31, viewpoint, france); ordinary PCR amplification apparatus (T100, BIO-RAD, singapore); fluorescent quantitative PCR apparatus (CFX Connect, BIO-RAD, singapore); ultraviolet-visible spectrophotometers (Nanodrop 2000, thermo, USA); microplate mini centrifuge (BE-6100, china, inc. Of lyben instruments, inc.); low skirt 96 well plates (transparent) (HSP 9601, bio-rad, USA); 6-well plates (Nest Biotech, china); optical adhesive seal film B (MSB 1001, bio-rad, USA).
Pentatetrazole (PTZ, lot A27O8L46880, shanghai Seiyaka Biotechnology Co., ltd.); dimethyl sulfoxide (DMSO, lot BCCD8942, sigma, switzerland); absolute ethanol (lot 20210107, national pharmaceutical systems chemical company, china); powerUp TM SYBR TM GreenMasterMix (lot 01145665, sammer femto technology (china), lithunia); fastKing cDNA first Strand Synthesis kit (genome removal) (lot number W0008, tiangen Biochemical technology (Beijing), inc., china); RNA-Quick Purification Kit (Rapid extraction kit for RNA) (lot 20220101,YiShan Biotech,China).
2. Detection method
Mtc assay
Zebra fish of 5dpf wild type AB strain were randomly selected in 6-well plates, and 30 animals were treated per well (experimental group). Peoney Oil (concentrations are shown in table 1) was given in water solution, and both normal control and model control were set at 3mL per well. After 24h treatment at 28 ℃, the PTZ is given to each of the other experimental groups except the normal control group in a water-soluble manner to establish a zebra fish insomnia model. After further treatment at 28℃for 1h, the MTC of the Peoney Oil was determined for the model zebra fish.
2.2. Evaluation of sleep improvement efficacy (phenotypic evaluation)
Zebra fish of 5dpf wild type AB strain were randomly selected in 6 well plates with 30 tails per well. Peoney Oil (concentrations are shown in table 2) was given in water, the positive control melatonin at a concentration of 125 μg/mL, and both the normal control and model control groups were set at a capacity of 3mL per well. After 24h treatment at 28 ℃, 10 zebra fish were randomly selected for each experimental group and transferred into 96-well plates at 1 tail/200 μl/well. The PTZ was given water-soluble to establish a zebra fish insomnia model in all experimental groups except the normal control group. Measuring the wakefulness activity and the wakefulness total time of the zebra fish within 1h by using a behavior analyzer, and evaluating the sleep improvement efficacy of the peoney Oil according to the statistical analysis results of the indexes; wherein, the arousal activity amount refers to the sum of the rapid movement distances of the zebra fish in 1h (the low speed is less than 4mm/s, the medium speed is 4-20mm/s and the rapid speed is more than 20 mm/s), and the arousal activity time refers to the sum of the rapid movement time of the zebra fish in 1 h. Statistical treatment results are expressed in mean+ -SE. Statistical analysis was performed with SPSS26.0 software, p <0.05 indicated that the differences were statistically significant. The respective administration concentrations of Peony seed Oil, acer truncatum Oil and VE are the same as those of Peony seed Oil composition (peoney Oil), and the same is followed.
2.3. Evaluation of sleep improving efficacy (Gene)
Zebra fish of 5dpf wild type AB strain were randomly selected in 6 well plates with 30 tails per well. Peoney Oil (concentrations are shown in table 3) was given in water, the positive control melatonin at a concentration of 125 μg/mL, and both the normal control and model control groups were set at a capacity of 3mL per well. After 24h treatment at 28 ℃, the PTZ is given to each of the other experimental groups except the normal control group in a water-soluble manner to establish a zebra fish insomnia model. After further treatment at 28 ℃ for 1 hour, the total RNA of each group of zebra fish is extracted by using an RNA rapid extraction kit, and the total RNA concentration and purity are determined by using an ultraviolet-visible spectrophotometer. 2.00. Mu.g of total RNA from a zebra fish sample was synthesized into 20.0. Mu.L of cDNA according to the first strand cDNA synthesis kit, and the expression of the beta-actin, mtnr1aa and gabra1 genes was detected by q-PCR. The relative RNA expression levels of the mtnr1aa and gabra1 genes were calculated using β -actin as an internal reference for gene expression. Statistical treatment results are expressed in mean+ -SE. Statistical analysis was performed with SPSS26.0 software, p <0.05 indicated that the differences were statistically significant.
3. Detection result
3.1.MTC
Under the experimental conditions, the MTC of the Peoney Oil to the model zebra fish is 0.078 mu L/mL. Details are shown in Table 1.
Table 1 samples improved sleep efficacy concentration fumbling experimental results (n=30)
3.2. Evaluation of sleep improvement efficacy (phenotypic evaluation)
Under the experimental conditions, peoney Oil has the effect of improving sleep, and is characterized by reduced arousal activity and total arousal time. See table 2, fig. 1, fig. 2 and fig. 3 for details.
Table 2. Results of the test for improving sleep efficacy (n=10)
P <0.01, p <0.001 compared to model control group
RNA extraction results and primer sequence information
At the experimental end point, total RNA of the zebra fish is extracted, the concentration of the RNA and the ratio A260/A280 (Table 3) are measured by an ultraviolet-visible light spectrophotometer, and the ratio A260/A280 is 1.8-2.2, which shows that the total RNA of the zebra fish obtained by extraction has better quality and can be used for the subsequent q-PCR experiment. The primer sequences are shown in Table 4.
TABLE 3 concentration of total RNA and A260/A280 ratio (n=30)
TABLE 4 primer sequence information
3.4. Evaluation of sleep improving efficacy (Gene)
Under the experimental conditions, the peoney Oil has the effect of improving sleep, and is specifically expressed as up-regulating the relative expression quantity of mtnr1aa and gabra1 genes. See table 5, fig. 4 and fig. 5 for details.
Table 5. Results of the test for improving sleep efficacy (n=3)
P <0.05, < p <0.01 compared to model control group
(II) evaluation of sleep improvement efficacy by separate application of peony seed oil, acer truncatum oil and VE
1. Detection material
1.1. Sample formulation information
The peony seed oil, the Acer truncatum oil and the VE are respectively heated and then prepared into 100 mu L/mL mother liquor by 10% DMSO, and the mother liquor is prepared for use.
Positive control: melatonin, white powder, lot number F1804064, shanghai Ala Biochemical technology Co., ltd.) was stored in the shade. Stock solution of 12.5mg/mL was prepared with DMSO and stored at-20 ℃.
1.2 test animals
Experimental animals under the same item 1.2'
1.3 instruments, consumables and reagents
1.3 instruments, consumables and reagents under the same item'
2. Detection method
Mtc assay
Specific assay methods are as described under (one) 2.1.MTC assay. Under the experimental conditions, the MTC for the respective administration of the peony seed oil, the Acer truncatum oil and the VE is 0.078 mu L/mL. Details are shown in Table 6.
Table 6. Sample sleep improvement efficacy concentration fumbling experimental results (n=30)
2.2. Evaluation of sleep improvement efficacy (phenotypic evaluation)
Specific assay method was 2.2. Sleep improvement efficacy assessment (phenotypic assessment) under item "(one). Under the experimental conditions, the peony seed oil, the acer truncatum oil and the VE have certain sleep improving effects, and are specifically characterized in that the arousal activity and the arousal total time are reduced; however, at the same concentration, their sleep improvement effect was lower than that of Peony seed Oil composition (peoney Oil). See Table 7 for details.
Table 7. Results of the test for improving sleep efficacy of samples (n=10)
P <0.01, p <0.001 compared to model control group
2.3. Evaluation of sleep improving efficacy (Gene)
Specific assay method is described under item (one) ". At the experimental end point, total RNA of the zebra fish is extracted, and the ratio of RNA A260/A280 is 1.8-2.2 as measured by an ultraviolet-visible light spectrophotometer, which shows that the total RNA of the zebra fish obtained by extraction has better quality and can be used for the subsequent q-PCR experiment.
Under the experimental condition, the peony seed oil, the Acer truncatum oil and the VE have certain sleep improving effects, and are specifically expressed by up-regulating the relative expression quantity of the mtnr1aa genes; however, at the same concentration, the effect of improving sleep is lower than that of the Peony seed Oil composition (peoney Oil), and the relative expression amount of the gabra1 gene is not obviously influenced. Details are shown in Table 8.
Table 8. Results of the test for improving sleep efficacy of samples (n=3)
P <0.05, < p <0.01 compared to model control group
In summary, in terms of improving sleep efficacy, the effects of separately administering Peony seed Oil, acer truncatum Oil and VE are lower than those of the Peony seed Oil composition (peoney Oil) at the same dosage.
Animal experiments prove that the invention comprises the following steps: the Peony seed Oil composition (peoney Oil) has the effect of improving sleep, is particularly characterized in that the arousal activity and the arousal total time are reduced, the relative expression of the mtnr1aa and gabra1 genes is up-regulated, and has better effect than independent Peony seed Oil, acer truncatum Oil and VE in the aspect of improving sleep, and has practical popularization and application values.
Claims (9)
1. A composition having sleep improving effect, characterized in that: the composite material is prepared from the following raw materials in parts by weight:
1-5 parts of peony seed oil, 1-5 parts of acer truncatum oil and 0.5-2.5 parts of vitamin E.
2. The composition of claim 1, wherein: the composite material is prepared from the following raw materials in parts by weight:
1 part of peony seed oil, 1 part of acer truncatum oil and 0.5 part of vitamin E.
3. The composition of claim 1, wherein: the peony seed oil contains linoleic acid in a relative content of more than 17% and alpha-linolenic acid in a relative content of more than 58%.
4. The composition of claim 1, wherein: the relative content of linoleic acid in the acer truncatum oil is more than 30%, the relative content of arachidonic acid is more than 12%, and the relative content of nervonic acid is more than 4%.
5. The composition according to any one of claims 1 to 4, wherein: the preparation is prepared by taking peony seed oil, acer truncatum oil and vitamin E as active ingredients and adding pharmaceutically acceptable auxiliary materials.
6. The composition of claim 5, wherein: the preparation is an external preparation.
7. The composition of claim 6, wherein: the external preparation is solution, emulsion, gel, aerosol, film coating agent, and emplastrum.
8. A method for preparing the composition of any one of claims 1 to 7, characterized in that: it comprises the following steps:
1) Weighing the raw materials according to the proportion;
2) Mixing the above materials, and adding pharmaceutically acceptable adjuvants.
9. Use of a composition according to any one of claims 1 to 7 for the preparation of a medicament for improving sleep.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211413126.2A CN115671169B (en) | 2022-11-11 | 2022-11-11 | A composition with sleep improving effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211413126.2A CN115671169B (en) | 2022-11-11 | 2022-11-11 | A composition with sleep improving effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115671169A CN115671169A (en) | 2023-02-03 |
| CN115671169B true CN115671169B (en) | 2024-01-30 |
Family
ID=85051925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211413126.2A Active CN115671169B (en) | 2022-11-11 | 2022-11-11 | A composition with sleep improving effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115671169B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102626227A (en) * | 2012-04-23 | 2012-08-08 | 昆明海之灵生物科技开发有限公司 | Acer truncatum flavone and acer truncatum nervonic acid soft capsules and preparation method thereof |
| CN105994691A (en) * | 2016-05-20 | 2016-10-12 | 洛阳泽达慧康医药科技有限公司 | Method for manufacturing blend oil with peony seed oil and acer truncatum oil |
| CN112386630A (en) * | 2019-08-19 | 2021-02-23 | 淄博鲁祥生物科技有限公司 | Brain-strengthening and intelligence-improving composition and preparation method and medical application thereof |
| CN113577228A (en) * | 2021-07-27 | 2021-11-02 | 株式会社健康事业资讯 | Composition for improving sleep and memory and preparation method and application thereof |
-
2022
- 2022-11-11 CN CN202211413126.2A patent/CN115671169B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102626227A (en) * | 2012-04-23 | 2012-08-08 | 昆明海之灵生物科技开发有限公司 | Acer truncatum flavone and acer truncatum nervonic acid soft capsules and preparation method thereof |
| CN105994691A (en) * | 2016-05-20 | 2016-10-12 | 洛阳泽达慧康医药科技有限公司 | Method for manufacturing blend oil with peony seed oil and acer truncatum oil |
| CN112386630A (en) * | 2019-08-19 | 2021-02-23 | 淄博鲁祥生物科技有限公司 | Brain-strengthening and intelligence-improving composition and preparation method and medical application thereof |
| CN113577228A (en) * | 2021-07-27 | 2021-11-02 | 株式会社健康事业资讯 | Composition for improving sleep and memory and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 湖南油用牡丹籽油的理化性质及脂肪酸组分分析;陈景震;李培旺;张良波;肖志红;吴苏喜;吴红;赵志伟;;经济林研究;第33卷(第04期);119-122页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115671169A (en) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008169174A (en) | Bergenin derivative having inflammatory cytokine production-inhibiting action, food preparation, cosmetic, antiinflammatory agent comprising the same | |
| HUE027480T2 (en) | Method for the industrial purification of biologically active phycotoxins | |
| KR20190125923A (en) | A composition for protecting respiratory or skin cells against fine dust using ALDH1A2, ALDH1A3 or ALDH3A2 and a method for screening the same | |
| CN108567955A (en) | A kind of pharmaceutical composition and preparation method thereof of prevention diabetic nephropathy | |
| CN115671169B (en) | A composition with sleep improving effect | |
| JP2007176814A (en) | Zeaxanthin derivative having inhibiting action on production of inflammatory cytokine, and food product preparation, cosmetics, and anti-inflammatory agent comprising same | |
| CN117731750A (en) | Traditional Chinese and Tibetan medicine composition with microcirculation improving, diuresis promoting and dampness eliminating functions | |
| Russo et al. | A new ginger extract characterization: Immunomodulatory, antioxidant effects and differential gene expression | |
| KR20130085106A (en) | Anti-bacterial or anti-inflammatory composition comprising extracts from flower of rosa hybrida as active ingredient | |
| RU2038086C1 (en) | Method for extracting biologically active product from wax moth larvae | |
| WO2018151334A1 (en) | Xanthine oxidase inhibitor and method for producing same | |
| CN1325485C (en) | Process of separating fucoxanthin from algae | |
| EP3897683B1 (en) | Cosmetic, pharmaceutical and nutraceutical use of an extract derived from cannabis sativa cell cultures | |
| Guinnin et al. | Acute toxicity evaluation of ethanolic extract of aristolochia albida duch. leaves on wistar rats liver and kidney functions | |
| SHARIPOVA et al. | Development of an anti-inflammatory extract from leaves and immature fruits of walnuts. | |
| JP2022006397A (en) | Barrier function enhancer | |
| Ban et al. | Phytochemical screening and study of in vitro antioxidant activities of the aqueous extract and the alcoholic (koutoukou extract) of Garcinia kola seeds (Guttiferea) collected in Abidjan (Ivory coast) | |
| RU2283006C1 (en) | Method for non-waste reprocessing of sea hedgehog roe | |
| CA2442260A1 (en) | Use of one or more shogaol(s) as an aphrodisiac | |
| JP6831049B2 (en) | Method for producing a grunge fluorolic acid derivative exhibiting an NF-κB inhibitory effect | |
| CN114540450B (en) | Hemp seed bioactive peptide for regulating HPRT1 gene and OAT1 protein and preparation method thereof | |
| TWI619499B (en) | Neuroprotection application of xylaria nigripes mycelium extract | |
| Islam | In vitro evaluation of thrombolytic and antioxidant scavenging activity of eichhornia crassipes | |
| JP2007176816A (en) | beta-AMYRIN DERIVATIVE HAVING INHIBITING ACTION ON PRODUCTION OF INFLAMMATORY CYTOKINE, AND FOOD PRODUCT PREPARATION, COSMETICS, AND ANTI-INFLAMMATORY AGENT COMPRISING SAME | |
| CN114349821B (en) | Application of frog skin antioxidant peptide and gene thereof in pharmacy and anti-wrinkle cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |